Related Experiment Videos
Hospital-acquired pneumonia: risk factors, microbiology, and treatment
1Division of Pulmonary and Critical Care Medicine, University of Michigan Medical Center, 3916 Tubman Center, Ann Arbor, MI 48109, USA. jlynch@umich.edu
Abstract:
Pneumonia complicates hospitalization in 0.5 to 2.0% of patients and is associated with considerable morbidity and mortality. Risk factors for hospital-acquired pneumonia (HAP) include mechanical ventilation for > 48 h, residence in an ICU, duration of ICU or hospital stay, severity of underlying illness, and presence of comorbidities. Pseudomonas aeruginosa, Staphylococcus aureus, and Enterobacter are the most common causes of HAP. Nearly half of HAP cases are polymicrobial. In patients receiving mechanical ventilation, P aeruginosa, Acinetobacter, methicillin-resistant S aureus, and other antibiotic-resistant bacteria assume increasing importance. Optimal therapy for HAP should take into account severity of illness, demographics, specific pathogens involved, and risk factors for antimicrobial resistance. When P aeruginosa is implicated, monotherapy, even with broad-spectrum antibiotics, is associated with rapid evolution of resistance and a high rate of clinical failures. For pseudomonal HAP, we advise combination therapy with an antipseudomonal beta-lactam plus an aminoglycoside or a fluoroquinolone (eg, ciprofloxacin).
Insights
Hospital-acquired pneumonia (HAP) affects up to 2% of patients, increasing mortality. Combination therapy is recommended for Pseudomonas aeruginosa HAP to prevent resistance and improve outcomes.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pulmonary Medicine
Background:
- Hospital-acquired pneumonia (HAP) affects 0.5-2.0% of hospitalized patients, contributing significantly to morbidity and mortality.
- Key risk factors for HAP include mechanical ventilation, ICU stay duration, and patient comorbidities.
- Common causative agents include Pseudomonas aeruginosa, Staphylococcus aureus, and Enterobacter, with polymicrobial infections frequent.
Purpose of the Study:
- To review risk factors, common pathogens, and optimal therapeutic strategies for hospital-acquired pneumonia (HAP).
- To emphasize the challenges posed by antibiotic-resistant bacteria in ventilated patients.
- To provide evidence-based recommendations for treating HAP, particularly infections caused by Pseudomonas aeruginosa.
Main Methods:
- Literature review of risk factors, causative agents, and treatment outcomes for HAP.
- Analysis of antimicrobial resistance patterns in hospital-acquired infections.
- Evaluation of therapeutic regimens for Pseudomonas aeruginosa HAP.
Main Results:
- Pseudomonas aeruginosa, Acinetobacter, and methicillin-resistant Staphylococcus aureus are significant pathogens in ventilated patients.
- Monotherapy for Pseudomonas aeruginosa HAP leads to resistance and treatment failure.
- Combination therapy is associated with better outcomes for pseudomonal HAP.
Conclusions:
- Optimal HAP therapy requires consideration of illness severity, patient demographics, pathogens, and resistance risk factors.
- Combination therapy, specifically an antipseudomonal beta-lactam plus an aminoglycoside or fluoroquinolone, is advised for Pseudomonas aeruginosa HAP.
- Addressing antimicrobial resistance is crucial for effective HAP management.